pyrazinamide has been researched along with Disease Models, Animal in 76 studies
pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen." | 8.12 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 8.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2." | 8.02 | Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. ( Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD, 2021) |
| "Through mutant selection on agar containing pyrazinoic acid (POA), the bioactive form of the prodrug pyrazinamide (PZA), we recently showed that missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1, and loss-of-function mutation of polyketide synthases Mas and PpsA-E involved in phthiocerol dimycocerosate synthesis, cause resistance to POA and PZA in Mycobacterium tuberculosis." | 7.85 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ( Dartois, V; Dick, T; Gopal, P; Lanoix, JP; Li, L; Nuermberger, E; Rasic, G; Sarathy, J; Tasneen, R; Yee, M, 2017) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 7.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 7.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| "Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance." | 7.78 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012) |
| "Aspirin (acetylsalicylic acid) or ibuprofen [2-(4-isobutyl-phenyl)-propionic acid] was administered to mice undergoing treatment of tuberculosis infection with pyrazinamide to determine if these non-steroidal anti-inflammatory drugs (NSAIDs) enhance pyrazinamide activity in vivo." | 7.74 | Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. ( Byrne, ST; Denkin, SM; Zhang, Y, 2007) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 7.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "To see whether sustained levels of pyrazinamide are available for prolonged periods after a single subcutaneous administration of a biodegradable polylactic-glycolic acid (PLGA) polymer containing the drug, studies were done to ascertain whether a single administration of isoniazid and pyrazinamide in separate PLGA polymers could offer chemotherapeutic protection against a heavy intravenous challenge of susceptible mice with a virulent strain of Mycobacterium tuberculosis similar to that rendered by daily administration of the two drugs for 8 weeks." | 7.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| " In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model." | 7.70 | Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999) |
| " However, further studies to identify the optimal statin and dosing are required." | 5.40 | Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014) |
| "Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens." | 5.34 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007) |
| "tuberculosis has transcriptional activity." | 5.31 | Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. ( Butcher, PD; Coates, AR; Dhillon, J; Hu, Y; Mangan, JA; Mitchison, DA; Sole, KM, 2000) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 4.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| " Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen." | 4.12 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022) |
| "We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2." | 4.02 | Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model. ( Bax, HI; de Steenwinkel, JEM; Keutzer, L; Pieterman, ED; Simonsson, USH; van den Berg, S; van der Meijden, A; Wang, H; Zimmerman, MD, 2021) |
| "In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration." | 3.88 | Impact of immunopathology on the antituberculous activity of pyrazinamide. ( Alvarez Cabrera, N; Blanc, L; Dartois, V; Dias-Freedman, I; Dick, T; Gengenbacher, M; Ioerger, T; Mina, M; O'Brien, P; Podell, BK; Prideaux, B; Sacchettini, J; Sarathy, JP; Savic, RM, 2018) |
| "Through mutant selection on agar containing pyrazinoic acid (POA), the bioactive form of the prodrug pyrazinamide (PZA), we recently showed that missense mutations in the aspartate decarboxylase PanD and the unfoldase ClpC1, and loss-of-function mutation of polyketide synthases Mas and PpsA-E involved in phthiocerol dimycocerosate synthesis, cause resistance to POA and PZA in Mycobacterium tuberculosis." | 3.85 | In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ( Dartois, V; Dick, T; Gopal, P; Lanoix, JP; Li, L; Nuermberger, E; Rasic, G; Sarathy, J; Tasneen, R; Yee, M, 2017) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 3.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 3.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| " After sporozoite inoculation and blood-stage cure of initial parasitemia with chloroquine, rhesus macaques were treated on subsequent relapses with chloroquine in conjunction with test regimens of approved drugs." | 3.78 | Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. ( Bennett, K; Deye, GA; Fracisco, S; Gettayacamin, M; Hansukjariya, P; Im-erbsin, R; Macareo, L; Magill, AJ; Ohrt, C; Rothstein, Y; Sattabongkot, J, 2012) |
| "Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance." | 3.78 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012) |
| " Between day 52 and 5 mo after infection, 10 of the 170 mice infected according to this protocol developed torticollis, including mice in treatment groups that received combination antibiotic therapy of rifampin-pyrazinamide or moxifloxacin-rifampin-pyrazinamide." | 3.77 | Torticollis in mice intravenously infected with Mycobacterium tuberculosis. ( DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM, 2011) |
| "TMC207, rifapentine, and moxifloxacin are in clinical testing for the treatment of tuberculosis." | 3.76 | Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. ( Andries, K; Gevers, T; Lounis, N, 2010) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 3.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "Aspirin (acetylsalicylic acid) or ibuprofen [2-(4-isobutyl-phenyl)-propionic acid] was administered to mice undergoing treatment of tuberculosis infection with pyrazinamide to determine if these non-steroidal anti-inflammatory drugs (NSAIDs) enhance pyrazinamide activity in vivo." | 3.74 | Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. ( Byrne, ST; Denkin, SM; Zhang, Y, 2007) |
| "To see whether sustained levels of pyrazinamide are available for prolonged periods after a single subcutaneous administration of a biodegradable polylactic-glycolic acid (PLGA) polymer containing the drug, studies were done to ascertain whether a single administration of isoniazid and pyrazinamide in separate PLGA polymers could offer chemotherapeutic protection against a heavy intravenous challenge of susceptible mice with a virulent strain of Mycobacterium tuberculosis similar to that rendered by daily administration of the two drugs for 8 weeks." | 3.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| " In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model." | 3.70 | Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999) |
| "In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M." | 1.48 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. ( Alameda-Martin, L; Coates, A; Davies, G; Harrison, T; Hu, Y; Liu, Y; Ortega-Muro, F; Pertinez, H, 2018) |
| "Pyrazinamide (PZA) is a critical component of current first-line TB therapy." | 1.48 | Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. ( Braunstein, M; Durham, PG; Hayden, JD; Hickey, AJ; Lin, FC; Miller, BK; Montgomery, SA; Rank, L; Welch, JT; Young, EF; Zulauf, KE, 2018) |
| "As current treatment of tuberculosis is burdensomely long, provoking non-adherence and drug resistance, effective short-course treatments are needed." | 1.48 | Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. ( Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A, 2018) |
| " The relative bias and relative imprecision of each pharmacokinetic parameter for each drug were derived and assessed to choose the final designs." | 1.43 | Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. ( Alameda, L; Chen, C; Ferrer, S; Ortega, F; Simonsson, US, 2016) |
| "Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections." | 1.43 | Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis. ( Betoudji, F; Lanoix, JP; Nuermberger, E, 2016) |
| " However, further studies to identify the optimal statin and dosing are required." | 1.40 | Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014) |
| " In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis." | 1.40 | Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. ( Dutta, NK; Karakousis, PC; Pinn, ML, 2014) |
| " This is despite the availability of antibiotics that have good activity against Mycobacterium tuberculosis in vitro and favorable pharmacokinetic profiles in plasma." | 1.38 | Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. ( Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D, 2012) |
| "Rifampin-treated BALB/c mice remained culture positive at 3 months." | 1.37 | Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. ( Ahmad, Z; Almeida, DV; Converse, PJ; Grosset, JH; Li, SY; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Zhang, M, 2011) |
| " We studied the effects of Ag85A DNA vaccine alone or in combination with rifampin (RFP) or pyrazinamide (PZA) for the treatment of MDR-TB in mice." | 1.37 | Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. ( Bai, X; Li, N; Li, Z; Liang, Y; Wang, L; Wu, X; Yang, Y; Yu, Q; Zhang, J, 2011) |
| " For the first 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice weekly." | 1.36 | Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. ( Ahmad, Z; Grosset, JH; Karakousis, PC; Nuermberger, EL; Peloquin, CA; Pinn, ML; Tasneen, R; Williams, KN, 2010) |
| "Treatment with rifampin and pyrazinamide was more effective than treatment with rifampin, isoniazid, and pyrazinamide at reducing the lung CFU count, consistent with past evidence of isoniazid's antagonism in this model." | 1.35 | Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. ( Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K, 2008) |
| "Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens." | 1.34 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007) |
| "tuberculosis has transcriptional activity." | 1.31 | Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. ( Butcher, PD; Coates, AR; Dhillon, J; Hu, Y; Mangan, JA; Mitchison, DA; Sole, KM, 2000) |
| "tuberculosis are treated with antibiotics (isoniazid and pyrazinamide), resulting in no detectable bacilli by organ culture." | 1.30 | Reactivation of latent tuberculosis: variations on the Cornell murine model. ( Chan, J; Flynn, JL; Joseph, H; Mohan, VP; Scanga, CA; Yu, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.26) | 18.2507 |
| 2000's | 17 (22.37) | 29.6817 |
| 2010's | 48 (63.16) | 24.3611 |
| 2020's | 7 (9.21) | 2.80 |
| Authors | Studies |
|---|---|
| Rullas, J | 1 |
| García, JI | 1 |
| Beltrán, M | 1 |
| Cardona, PJ | 1 |
| Cáceres, N | 1 |
| García-Bustos, JF | 1 |
| Angulo-Barturen, I | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Tasneen, R | 10 |
| Garcia, A | 1 |
| Converse, PJ | 5 |
| Zimmerman, MD | 2 |
| Dartois, V | 6 |
| Kurbatova, E | 1 |
| Vernon, AA | 2 |
| Carr, W | 1 |
| Stout, JE | 1 |
| Dooley, KE | 1 |
| Nuermberger, EL | 12 |
| Ding, Y | 1 |
| Zhu, H | 1 |
| Fu, L | 1 |
| Zhang, W | 2 |
| Wang, B | 2 |
| Guo, S | 1 |
| Chen, X | 1 |
| Wang, N | 1 |
| Liu, H | 1 |
| Lu, Y | 1 |
| Glenn, SM | 1 |
| Turapov, O | 1 |
| Makarov, V | 1 |
| Kell, DB | 1 |
| Mukamolova, GV | 1 |
| Sharma, V | 1 |
| Kaur, R | 1 |
| Sharma, VL | 1 |
| Pieterman, ED | 1 |
| Keutzer, L | 1 |
| van der Meijden, A | 1 |
| van den Berg, S | 1 |
| Wang, H | 1 |
| Simonsson, USH | 2 |
| Bax, HI | 3 |
| de Steenwinkel, JEM | 4 |
| Chiwala, G | 1 |
| Liu, Z | 1 |
| Mugweru, JN | 1 |
| Khan, SA | 1 |
| Bate, PNN | 1 |
| Yusuf, B | 1 |
| Hameed, HMA | 1 |
| Fang, C | 1 |
| Tan, Y | 1 |
| Guan, P | 1 |
| Hu, J | 1 |
| Tan, S | 1 |
| Liu, J | 2 |
| Zhong, N | 1 |
| Zhang, T | 1 |
| Dutta, NK | 3 |
| Pinn, ML | 6 |
| Karakousis, PC | 7 |
| de Knegt, GJ | 4 |
| Dickinson, L | 1 |
| Pertinez, H | 3 |
| Evangelopoulos, D | 1 |
| McHugh, TD | 1 |
| Bakker-Woudenberg, IAJM | 1 |
| Davies, GR | 1 |
| Li, SY | 4 |
| Tyagi, S | 8 |
| Soni, H | 1 |
| Mdluli, K | 1 |
| Mourik, BC | 2 |
| Verbon, A | 2 |
| Mouton, JW | 1 |
| Liu, Y | 2 |
| Ortega-Muro, F | 2 |
| Alameda-Martin, L | 2 |
| Harrison, T | 1 |
| Davies, G | 2 |
| Coates, A | 2 |
| Hu, Y | 3 |
| Svensson, RJ | 1 |
| Blanc, L | 1 |
| Sarathy, JP | 1 |
| Alvarez Cabrera, N | 1 |
| O'Brien, P | 1 |
| Dias-Freedman, I | 1 |
| Mina, M | 1 |
| Sacchettini, J | 2 |
| Savic, RM | 1 |
| Gengenbacher, M | 1 |
| Podell, BK | 1 |
| Prideaux, B | 1 |
| Ioerger, T | 2 |
| Dick, T | 2 |
| Montgomery, SA | 1 |
| Young, EF | 1 |
| Durham, PG | 1 |
| Zulauf, KE | 1 |
| Rank, L | 1 |
| Miller, BK | 1 |
| Hayden, JD | 1 |
| Lin, FC | 1 |
| Welch, JT | 1 |
| Hickey, AJ | 1 |
| Braunstein, M | 1 |
| Lee, BY | 1 |
| Clemens, DL | 1 |
| Silva, A | 1 |
| Dillon, BJ | 1 |
| Masleša-Galić, S | 1 |
| Nava, S | 1 |
| Ho, CM | 1 |
| Horwitz, MA | 1 |
| Khan, N | 1 |
| Mendonca, L | 1 |
| Dhariwal, A | 1 |
| Fontes, G | 1 |
| Menzies, D | 1 |
| Xia, J | 1 |
| Divangahi, M | 1 |
| King, IL | 1 |
| Hussain, T | 1 |
| Gupta, RK | 1 |
| K, S | 1 |
| Khan, MS | 1 |
| Hussain, MD | 1 |
| Arif, MD | 1 |
| Hussain, A | 1 |
| Faiyazuddin, MD | 1 |
| Rao, CV | 1 |
| Ahmad, Z | 3 |
| Minkowski, A | 2 |
| Peloquin, CA | 7 |
| Grosset, JH | 9 |
| Alsultan, A | 1 |
| Gniadek, TJ | 1 |
| Belchis, DA | 1 |
| Mdluli, KE | 4 |
| Wang, P | 1 |
| Wang, L | 2 |
| Bai, Y | 1 |
| Kang, J | 1 |
| Hao, Y | 1 |
| Luo, T | 1 |
| Shi, C | 1 |
| Xu, Z | 1 |
| Manca, C | 1 |
| Koo, MS | 1 |
| Peixoto, B | 1 |
| Fallows, D | 1 |
| Kaplan, G | 1 |
| Subbian, S | 1 |
| Jaydeokar, AV | 1 |
| Bandawane, DD | 1 |
| Bibave, KH | 1 |
| Patil, TV | 1 |
| Skerry, C | 2 |
| Bruiners, N | 1 |
| Pine, R | 1 |
| Gennaro, ML | 1 |
| Eun, JW | 1 |
| Bae, HJ | 1 |
| Shen, Q | 1 |
| Park, SJ | 1 |
| Kim, HS | 1 |
| Shin, WC | 1 |
| Yang, HD | 1 |
| Jin, CY | 1 |
| You, JS | 1 |
| Kang, HJ | 1 |
| Kim, H | 1 |
| Ahn, YM | 1 |
| Park, WS | 1 |
| Lee, JY | 1 |
| Nam, SW | 1 |
| Williams, K | 3 |
| Amoabeng, O | 1 |
| Upton, AM | 1 |
| ten Kate, MT | 1 |
| van Soolingen, D | 1 |
| Aarnoutse, R | 1 |
| Boeree, MJ | 1 |
| Bakker-Woudenberg, IA | 1 |
| de Steenwinkel, JE | 1 |
| Betoudji, F | 2 |
| Yang, T | 1 |
| Mendel, CM | 1 |
| Lanoix, JP | 3 |
| Ormond, A | 1 |
| Kaya, F | 1 |
| Nuermberger, E | 6 |
| Swanson, RV | 1 |
| Ammerman, NC | 2 |
| Ngcobo, B | 1 |
| Adamson, J | 1 |
| Moodley, C | 1 |
| Dorasamy, A | 1 |
| Moodley, S | 1 |
| Mgaga, Z | 1 |
| Bester, LA | 1 |
| Singh, SD | 1 |
| Almeida, DV | 2 |
| Schipani, A | 1 |
| Chen, C | 1 |
| Ortega, F | 1 |
| Alameda, L | 1 |
| Ferrer, S | 1 |
| Simonsson, US | 1 |
| Robertson, GT | 1 |
| Scherman, MS | 1 |
| Bruhn, DF | 1 |
| Hastings, C | 1 |
| McNeil, MR | 1 |
| Butler, MM | 1 |
| Bowlin, TL | 1 |
| Lee, RB | 1 |
| Lee, RE | 1 |
| Lenaerts, AJ | 6 |
| Gopal, P | 1 |
| Yee, M | 1 |
| Sarathy, J | 1 |
| Rasic, G | 1 |
| Li, L | 1 |
| Lounis, N | 3 |
| Gevers, T | 2 |
| Van Den Berg, J | 1 |
| Andries, K | 4 |
| Grosset, J | 2 |
| Rosenthal, IM | 4 |
| Zhang, M | 4 |
| Almeida, D | 5 |
| Veziris, N | 3 |
| Ibrahim, M | 2 |
| Chauffour, A | 1 |
| Truffot-Pernot, C | 3 |
| Jarlier, V | 2 |
| Murugaiyah, V | 1 |
| Chan, KL | 1 |
| Rao, NA | 1 |
| Albini, TA | 1 |
| Kumaradas, M | 1 |
| Fraig, MM | 1 |
| Williams, KN | 4 |
| Ordway, DJ | 1 |
| Shanley, CA | 1 |
| Caraway, ML | 1 |
| Orme, EA | 1 |
| Bucy, DS | 1 |
| Hascall-Dove, L | 1 |
| Henao-Tamayo, M | 1 |
| Harton, MR | 1 |
| Shang, S | 1 |
| Ackart, D | 1 |
| Kraft, SL | 1 |
| Basaraba, RJ | 2 |
| Orme, IM | 3 |
| Shi, W | 1 |
| Zhang, Y | 2 |
| Cheigh, CI | 1 |
| Senaratne, R | 1 |
| Uchida, Y | 1 |
| Casali, N | 1 |
| Kendall, LV | 2 |
| Riley, LW | 1 |
| Mitchison, DA | 2 |
| Liang, Y | 1 |
| Wu, X | 1 |
| Zhang, J | 1 |
| Yang, Y | 1 |
| Bai, X | 1 |
| Yu, Q | 1 |
| Li, N | 1 |
| Li, Z | 1 |
| Magden, ER | 1 |
| Weiner, CM | 1 |
| Gilliland, JC | 2 |
| DeGroote, MA | 1 |
| Kjellsson, MC | 1 |
| Via, LE | 1 |
| Goh, A | 1 |
| Weiner, D | 1 |
| Low, KM | 1 |
| Kern, S | 1 |
| Pillai, G | 1 |
| Barry, CE | 1 |
| De Groote, MA | 1 |
| Gruppo, V | 2 |
| Woolhiser, LK | 1 |
| Harper, J | 1 |
| Davis, SL | 1 |
| Weir, M | 1 |
| Kramnik, I | 2 |
| Bishai, WR | 4 |
| Pomper, MG | 1 |
| Jain, SK | 1 |
| Jenh, CH | 1 |
| Cox, MA | 1 |
| Cui, L | 1 |
| Reich, EP | 1 |
| Sullivan, L | 1 |
| Chen, SC | 1 |
| Kinsley, D | 1 |
| Qian, S | 1 |
| Kim, SH | 1 |
| Rosenblum, S | 1 |
| Kozlowski, J | 1 |
| Fine, JS | 1 |
| Zavodny, PJ | 1 |
| Lundell, D | 1 |
| Driver, ER | 1 |
| Ryan, GJ | 1 |
| Hoff, DR | 1 |
| Irwin, SM | 1 |
| Deye, GA | 1 |
| Gettayacamin, M | 1 |
| Hansukjariya, P | 1 |
| Im-erbsin, R | 1 |
| Sattabongkot, J | 1 |
| Rothstein, Y | 1 |
| Macareo, L | 1 |
| Fracisco, S | 1 |
| Bennett, K | 1 |
| Magill, AJ | 1 |
| Ohrt, C | 1 |
| Pym, AS | 1 |
| Wallengren, K | 1 |
| Hafner, R | 1 |
| Lalloo, U | 1 |
| Swindells, S | 1 |
| Smirnova, TG | 1 |
| Chernousova, LN | 1 |
| Andreevskaia, SN | 1 |
| Nikolaeva, GM | 1 |
| Johnson, CM | 1 |
| Marrieta, KS | 1 |
| Rosenthal, I | 2 |
| Aubry, A | 1 |
| Byrne, ST | 1 |
| Denkin, SM | 1 |
| Chaisson, RE | 1 |
| Gangadharam, PR | 1 |
| Geeta, N | 1 |
| Hsu, YY | 1 |
| Wise, DL | 1 |
| Scanga, CA | 1 |
| Mohan, VP | 1 |
| Joseph, H | 1 |
| Yu, K | 1 |
| Chan, J | 1 |
| Flynn, JL | 1 |
| Lenaerts, AM | 2 |
| Chase, SE | 2 |
| Chmielewski, AJ | 1 |
| Cynamon, MH | 2 |
| Mangan, JA | 1 |
| Dhillon, J | 1 |
| Sole, KM | 1 |
| Butcher, PD | 1 |
| Coates, AR | 1 |
| Jimonet, P | 1 |
| Bohme, GA | 1 |
| Bouquerel, J | 1 |
| Boireau, A | 1 |
| Damour, D | 1 |
| Debono, MW | 1 |
| Genevois-Borella, A | 1 |
| Hardy, JC | 1 |
| Hubert, P | 1 |
| Manfré, F | 1 |
| Nemecek, P | 1 |
| Pratt, J | 1 |
| Randle, JC | 1 |
| Ribeill, Y | 1 |
| Stutzmann, JM | 1 |
| Vuilhorgne, M | 1 |
| Mignani, S | 1 |
| Skakun, NP | 1 |
| Slivka, IuI | 1 |
1 review available for pyrazinamide and Disease Models, Animal
| Article | Year |
|---|---|
[Trends in tuberculosis treatment duration].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2006 |
75 other studies available for pyrazinamide and Disease Models, Animal
| Article | Year |
|---|---|
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; E | 2010 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Anima | 2022 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li | 2022 |
Dimethyl fumarate eliminates differentially culturable
Topics: Animals; Antitubercular Agents; Dimethyl Fumarate; Disease Models, Animal; Humans; Isoniazid; Mice; | 2022 |
Ameliorative potential of Adhatoda vasica against anti-tubercular drugs induced hepatic impairments in female Wistar rats in relation to oxidative stress and xeno-metabolism.
Topics: Alkaloids; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced | 2021 |
Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2021 |
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal; | 2021 |
Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Synergism; Drug Therapy | 2017 |
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model.
Topics: Animals; Antitubercular Agents; Bacterial Load; Colony Count, Microbial; Disease Models, Animal; DNA | 2017 |
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; | 2017 |
Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Femal | 2017 |
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Thera | 2018 |
Improving treatment outcome assessment in a mouse tuberculosis model.
Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combinat | 2018 |
Impact of immunopathology on the antituberculous activity of pyrazinamide.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Humans; Microbial Viability; Mycobac | 2018 |
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis.
Topics: Aerosols; Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Therapy, Comb | 2018 |
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; D | 2018 |
Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug-Related Side Effects and Adverse | 2019 |
Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fema | 2012 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease | 2013 |
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinic | 2013 |
Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.
Topics: Acyltransferases; Animals; Antigens, Bacterial; Antitubercular Agents; Bacteria; Bacterial Load; Bac | 2014 |
Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection.
Topics: Animals; Antitubercular Agents; Biomarkers; Cytokines; Disease Models, Animal; Female; Gene Expressi | 2013 |
Hepatoprotective potential of Cassia auriculata roots on ethanol and antitubercular drug-induced hepatotoxicity in experimental models.
Topics: Animals; Antioxidants; Antitubercular Agents; Cassia; Chemical and Drug Induced Liver Injury; Diseas | 2014 |
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cell Line; Colony Count, Microbial; Disease Models, | 2014 |
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid | 2014 |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
Topics: Animals; Biomarkers; Carbamazepine; Chemical and Drug Induced Liver Injury; Chlorpromazine; Disease | 2015 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, | 2015 |
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combi | 2014 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Admin | 2016 |
Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Genome, Bacteria | 2016 |
Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Drug Therapy, Co | 2016 |
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Combinations; Drug Therapy | 2016 |
Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Female; Isoniazid; Mice; | 2016 |
Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Ethambutol; Isoniazid; Mice, Inbred C5 | 2016 |
Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; L | 2017 |
In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Carboxy-Lyases; Culture Media; Disease Models, A | 2017 |
Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin | 2008 |
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; | 2008 |
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin | 2009 |
Mechanisms of antihyperuricemic effect of Phyllanthus niruri and its lignan constituents.
Topics: Animals; Disease Models, Animal; Drug Synergism; Gout Suppressants; Hyperuricemia; Inhibitory Concen | 2009 |
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2009 |
Experimental ocular tuberculosis in guinea pigs.
Topics: Aerosols; Animals; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; Guinea Pigs; Isoni | 2009 |
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Guinea Pigs; Isoniazid; Lung; Mice; | 2010 |
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.
Topics: Animals; Animals, Outbred Strains; Antitubercular Agents; Biomarkers; CD8-Positive T-Lymphocytes; Di | 2010 |
PhoY2 but not PhoY1 is the PhoU homologue involved in persisters in Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Colony Count, Microbial; Disease Models, Animal; | 2010 |
Posttreatment reactivation of tuberculosis in mice caused by Mycobacterium tuberculosis disrupted in mce1R.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Female; Humans; Isoniazi | 2010 |
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Femal | 2010 |
Activity of pyrazinamide in the guinea pig model of tuberculosis.
Topics: Animals; Antitubercular Agents; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Therapy, Co | 2010 |
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antitubercular; Antitubercular Agents; Cortisone; Di | 2011 |
Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs.
Topics: Acyltransferases; Animals; Antigens, Bacterial; Antitubercular Agents; Colony Count, Microbial; Comb | 2011 |
Torticollis in mice intravenously infected with Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combin | 2011 |
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug | 2012 |
Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; I | 2012 |
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expres | 2012 |
A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Autoimmune Diseases; Chemotaxis, Leukocyte; | 2012 |
Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Granuloma; Metronidazole; Mice; Mice, Inbred | 2012 |
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Administra | 2012 |
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Evaluation, Preclinical; Macaca mu | 2012 |
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.
Topics: Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anima | 2012 |
[Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; | 2004 |
Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.
Topics: Alanine Transaminase; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combinat | 2005 |
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C | 2006 |
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Aspirin; Disease Models, An | 2007 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; | 2007 |
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug | 2008 |
Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
Topics: Administration, Oral; Analysis of Variance; Animals; Antitubercular Agents; Biocompatible Materials; | 1999 |
Reactivation of latent tuberculosis: variations on the Cornell murine model.
Topics: Animals; Antitubercular Agents; Dexamethasone; Disease Models, Animal; Genetic Variation; Glucocorti | 1999 |
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C | 1999 |
Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Disease Models, Animal; Drug Therapy, Co | 2000 |
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2000 |
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Combinatorial Ch | 2001 |
[Effectiveness of tocopherol and anti-hypoxic agents in liver damage caused by antitubercular agents].
Topics: Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hepatitis, An | 1991 |